Comparison of the prevalence of major transfusion-transmitted infections among iranian blood donors using confidential unit exclusion in an Iranian population

Hepatitis Monthly

Volumn 11, Issue 1, 2011, Pages 11-13

  Khoda, Azadeh Omid ^a   Gharehbaghian, Ahmad ^a   Jamali, Mostafa ^a   Beigi, Naser Ahmad ^b,c   Hashemi, Seyed Mahmoud ^b,c   Rahimi, Abas ^d   Soleimani, Masoud ^b,c  

^a IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c Stem Cell Technology Institute   (Iran)

^d UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Blood donors; Confidential unit; Exclusion; Iranian; Risk factors

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ARTICLE; BLOOD DONOR; BLOOD SAFETY; CLINICAL EFFECTIVENESS; CONFIDENTIAL EXCLUSION UNIT; CONTROLLED STUDY; DISEASE TRANSMISSION; DONOR SELECTION; FEMALE; HUMAN; INFECTION RISK; IRAN; MAJOR CLINICAL STUDY; MALE; SEROPREVALENCE;

EID: 79956202461     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Moniri R, Mosayebii Z, Mossavi GA. Seroprevalence of Cytomegalovirus, Hepatitis B, Hepatitis C and Human Immunodeficiency Virus Antibodies among Volunteer Blood Donors. Iran J Public Health. 2004;33(4):38-42.
2. FDA. Additional recommendations for reducing further the number of units of blood and plasma donated for transfusion or for further manufacture by persons at increased risk of HTLV-III \LAV infection. US Food and Drug Administration: Department Of Health And Human Services; 1986. Report No.: 1998N-0046
3. Pindyck J, Waldman A, Zang E, Oleszko W, Lowy M, Bianco C. Measures to decrease the risk of acquired immunodeficiency syndrome transmission by blood transfusion. Evidence of volunteer blood donor cooperation. Transfusion. 1985;25(1):3-9.
4. Petersen LR, Lackritz E, Lewis WF, Smith DS, Herrera G, Raimondi V, et al. The effectiveness of the confidential unit exclusion option. Transfusion. 1994;34(10):865-9.
5. Korelitz JJ, Williams AE, Busch MP, Zuck TF, Ownby HE, Matijas LJ, et al. Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclusion process: the Retrovirus Epidemiology Donor Study. Transfusion. 1994;34(10):870-6.
6. Dodd RY, Notari EPt, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42(8):975-9.
7. Watkins K. Human Development Report 2007/2008 Iran. UNDP: Macmillan; 2007 [updated 2007; cited 2007]; Available from: http://hdr.undp.org/en/media/HDR_20072008_EN_Complete.pdf.
8. Brennan MT, Hewitt PE, Moore C, Hall G, Barbara JA. Confidential unit exclusion: the North London Blood Transfusion Centre's experience. Transfus Med. 1995;5(1):51-6.
9. Zou S, Notari EPt, Musavi F, Dodd RY. Current impact of the confidential unit exclusion option. Transfusion. 2004;44(5):651-7.
10. Cruze RE. Confidential unit exclusion in blood donors and associated factors. Revis Mexic de Pato Clín. 1999; 46:147-50.
11. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005;8(2):84-90.
12. Cheraghali AM, Abolghasemi H. Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience. Haemophilia. 2009;15(2):487-93.
13. Vahid T, Alavian SM, Kabir A, Kafaee J, Yektaparast B. Hepatitis B prevalence and risk factors in blood donors in Ghazvin, IR. Iran. Hepat Mon. 2005;5(4):117-22.
14. Alavian SM, Mostajabi P, Malekzadeh R. Evaluation of hepatitis B transmission risk factors in Tehran blood donors. Govaresh. 2004;9:169-75